Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: This study set out to determine the change in quality of life (QoL) and healthcare utilization during 2 years of growth hormone (GH) replacement therapy in adults with GH deficiency. Data were compared from three European countries. Design: Analysis was made from KIMS, the Pfizer International Metabolic Database on adult GH deficiency. Methods: QoL and healthcare utilization were measured at baseline and after 1 and 2 years of GH replacement in patient cohorts from Sweden (n = 302), The Netherlands (n = 103) and Germany (n = 98). QoL was assessed by the QoL-Assessment in Growth Hormone Deficient Adults (QoL-AGHDA) questionnaire, and the KIMS Patient Life Situation Form was used to evaluate healthcare utilization. Results: QoL improved significantly (P < 0.0001) and comparably in all three cohorts. The improvement was seen during the first year of treatment and QoL remained improved during the second year. The number of days in hospital was reduced by 83% (P < 0.0001) during GH replacement. There were no country-specific differences either at baseline or during follow-up. The same was true for the number of days of sick leave (reduction of 63%; P = 0.0004). Significant reductions were recorded in the number of doctor visits in each of the three cohorts after 2 years of GH replacement (P < 0.05). Conclusions: This study provides a detailed comparative analysis of GH replacement therapy in GHD patients in three European countries. Despite some differences in treatment strategies, the beneficial effects on QoL, patient-reported outcomes and healthcare utilization are essentially similar in the healthcare environment of Western European countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Growth hormone treatment affects brain neurotransmitters and thyroxine
Burman, P., Hetta, J., Wide, L., Månsson, J., Ekman, R., & Karlsson, F. A. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.617439.x · Cited by 126
Cited by
The growth hormone receptor: mechanism of activation and clinical implications
Brooks, A. J., & Waters, M. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.123 · Cited by 357
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
Rehabilitation in Endocrine Patients: A Novel Psychosomatic Approach
Sonino, N., & Fava, G. A. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000107558 · Cited by 33
Holmer, H., Svensson, J., Rylander, L., Johannsson, G., Rosén, T., Bengtsson, B.-Å., Thorén, M., Höybye, C., Degerblad, M., Bramnert, M., et al. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.09.008 · Cited by 16
“A few studies based on data from a large pharmaco-epidemiological surveillance program, have demonstrated reduced health care utilization with GH replacement for 1—3 years with reductions in number of out-patient visits (other than routine monitoring of therapy), days in hospital, and days of sick leave (Hernberg-Ståh…”
BackgroundSelf-citation
Metadata
- Authors
- Saller, B., Mattsson, A. F., Kann, P. H., Koppeschaar, H. P., Svensson, J., Pompen, M., & Koltowska-Häggström, M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06
- Volume
- 154
- Issue
- 6
- Pages
- 843-850
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2155440342
- Cited by
- 44
- References
- 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany. https://app.cochat.ai/papers/10.1530/eje.1.02149
- The paper
- Saller, B., Mattsson, A. F., Kann, P. H., Koppeschaar, H. P., Svensson, J., Pompen, M., & Koltowska-Häggström, M. (2006). Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany. European Journal of Endocrinology. https://doi.org/10.1530/eje.1.02149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.